ICLRICON Public Limited Company

$185.21-1.7% 1Y

$185.21

$80.0852 weeks$202.92

Is the price fair?

Fair

Neither cheap nor expensive: modest expectations priced in, but at the top of its own P/E range.

1 good, 1 to watch, 1 without data

What the price assumes~+3% a yearderived · Jun 30, 2026

Priced for ~3% a year FCF growth. The price bakes in little to no growth.

Vs its own P/E rangedearer than 88% of its own historyderived

Expensive vs its own history: P/E 51.7 vs a 29.2 median over 40 quarters (+77% vs median).

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

ICON Public Limited Company trades at 356× earnings against 36.7× for the median Diagnostics & Research name, more expensive than its own group.

356

Trailing P/E · Diagnostics & Research median 36.7 · 9.70× the median: the market pays up for this one

Price / sales: 1.62
Price / sales · as of 2026-Q2
Free cash flow yield: 6.2%
Free cash flow yield · Diagnostics & Research median 2.9%
Growth the price implies: +2.7%
Growth the price implies · The price pays for +2.7% free cash flow growth a year for a decade; the business has delivered +32% a year over the last three.

Details›

What the market has paid for these earnings: 40 quarters of its own multiple × $0.52 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$11.48
Its own P/E history, median	$15.18
Its own P/E history, upper quartile	$21.67
52-week range	$80.08 – $202.92
Today	$185.21

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.